



### United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/018,716	03/28/2002	Andrew R. Labarbera	91830/0476600	1627
7590 08/10/2005			EXAMINER	
Frost Brown Todd 2200 PNC Center			MARVICH, MARIA	
201 East Fifth Street			ART UNIT	PAPER NUMBER
Cincinnati, OH 45202			1633	
			DATE MAIL ED. 09/10/200	•

DATE MAILED: 08/10/200

Please find below and/or attached an Office communication concerning this application or proceeding.



# UNITED STATES DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office

DATE MAILED:

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION		ATTORNEY DOCKET NO.
	. ,			
			EXAMINER	
	·			,
			ART UNIT	PAPER
		·		805
			•	

Please find below and/or attached an Office communication concerning this application or proceeding.

#### **Commissioner for Patents**

The application contains sequence disclosures that are encompassed by the definition for nucleotide and/or amino acid sequences set forth in 37 C.F.R. 1.821(a)(1) and (a)(2). Specifically, the copmuter readable format copmrises an error as detailed in the accompanying error report. Therefore, the application fails to comply with the requirements of 37 C.F.R. 1.821(a)(1) and (a)(2) for the reasons set forth in the attached Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence Disclosures And/Or Amino Acid Sequence Disclosures.

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the reply.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Maria B Marvich, PhD whose telephone number is (703) 605-1207. The examiner can normally be reached on M-F (6:30-3:00). If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Remy Yucell, PhD can be reached on (703) 305-1998. The fax phone numbers for the organization where this application or proceeding is assigned are (571) 273-8300 for regular communications and (703) 305-4242 for After Final communications. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to receptionist whose telephone number is (703) 308-0196.

Maria B Marvich, PhD Examiner Art Unit 1633

> DANIEL M. SULLIVAN PATENT EXAMINER

#### Application No. Applicant(s) 10/018716 LaBarbera et al **Notice to Comply** Art Unit Examiner 1633 M. Marvich NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES** Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)). The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s): 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence" Listing" as required by 37 C.F.R. 1.821(c). 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e). 7. Other. Applicant Must Provide: An initial or substitute computer readable form (CRF) copy of the "Sequence Listing". oxtimes An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification. oxtimes A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d). For questions regarding compliance to these requirements, please contact: For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212 Patentin Software Program Support Technical Assistance......703-287-0200 To Purchase Patentin Software......703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

# STIC Biotechnology Systems Branch

## RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,

2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE <u>CHECKER VERSION 4.2.2 PROGRAM</u>, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

- 1. EFS-Bio (<a href="http://www.uspto.gov/ebc/efs/downloads/documents.htm">http://www.uspto.gov/ebc/efs/downloads/documents.htm</a>, EFS Submission User Manual ePAVE)
- 2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
- 3. Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 01/14/05): U.S. Patent and Trademark Office, Mail Stop Sequence, Customer Window, Randolph Building, 401 Dulany Street. Alexandria, VA 22314

Revised 01/24/05

### Raw Sequence Listing Error Summary

	10/-10 Q1/ A
ERROR DETECTED	SUGGESTED CORRECTION SERIAL NUMBER: 10/018,716 A
	PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE
Wrapped Nucleics Wrapped Aminos	The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."
·2Invalid Line Length	The rules require that a line not exceed 72 characters in length. This includes white spaces.
3Misaligned Amino Numbering	The numbering under each 5th amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.
4Non-ASCII	The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.
5Variable Length	Sequence(s)contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.
6Patentin 2.0 "bug"	A "bug" in Patentln version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) Normally, Patentln would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.
7Skipped Sequences (OLD RULES)	Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence:  (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)  (i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading)  (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)  This sequence is intentionally skipped
	Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.
8Skipped Sequences (NEW RULES)	Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence. <210> sequence id number <400> sequence id number 000
9Use of n's or Xaa's (NEW RULES)	Use of n's and/or Xaa's have been detected in the Sequence Listing.  Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present.  In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.
10Invalid <213> Response	Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence
11Use of <220>	Sequence(s) missing the <220> "Feature" and associated numeric identifiers and responses.  Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section. (29) Homo Sopiens, (See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules) Synthematical Control of the Control of Sequence Rules of Sequence Rules) Synthematical Register, "06/01/1998, Vol. 63, No. 104, pp. 29631-32)
12Patentin 2.0 "bug"	Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.
13 Misuse of n/Xaa	"n" can only represent a single nucleotide; "Xaa" can only represent a single amino acid

AMC - Biotechnology Systems Branch - 09/09/2003



IFW16

RAW SEQUENCE LISTING

DATE: 03/04/2005

PATENT APPLICATION: US/10/018,716A

TIME: 15:21:51

Input Set : D:\LaBarbara 0476600.txt Output Set: N:\CRF4\03042005\J018716A.raw

```
4 <110> APPLICANT: Labarbera, Andrew
             Wang, YiFang
             Zhu, ChangHong
     8 <120> TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDES FOR FERTILITY
             AND MENSTRUAL CYCLE REGULATION AND FOR CHEMOPREVENTIVE AND
     9
    10
             CHEMOTHERAPEUTIC USE
    12 <130> FILE REFERENCE: 91830/0476600
    14 <140> CURRENT APPLICATION NUMBER: 10/018,716A
C--> 15 <141> CURRENT FILING DATE: 2002-03-28
    17 <150> PRIOR APPLICATION NUMBER: 60/136,489
    18 <151> PRIOR FILING DATE: 1999-05-28
    20 <150> PRIOR APPLICATION NUMBER: 60/158,612
    21 <151> PRIOR FILING DATE: 1999-10-08
    23 <150> PRIOR APPLICATION NUMBER: US00/13488
                                                                        Does Not Comply
    24 <151> PRIOR FILING DATE: 2000-05-16
                                                                    Corrected Diskette Needer
    26 <160> NUMBER OF SEQ ID NOS: 4
    28 <170> SOFTWARE: FastSEQ for Windows Version 4.0
                                    invalid response- see ten 10 on Euro Sammay
    30 <210> SEQ ID NO: 1
    31 <211> LENGTH: 18
    32 <212> TYPE: DNA
    33 <213> ORGANISM: (Nucleic Acid
    35 <400> SEQUENCE: 1
                                                                           18
    36 gagcagggcc ataattat
    38 <210> SEQ ID NO: 2
    39 <211> LENGTH: 18
    40 <212> TYPE: RNA
    41 <213> ORGANISM: (Nucleic Acid
    43 <400> SEQUENCE: 2
                                                                           18
    44 auaauuaugg cccugcuc
    46 <210> SEQ ID NO: 3
    47 <211> LENGTH: 18
    48 <212> TYPE: DNA 🗲
    49 <213> ORGANISM: \Nucleic Acid
    51 <400> SEQUENCE: 3
                                                                           18
    52 gagcaaggac atgattat
    54 <210> SEQ ID NO: 4
    55 <211> LENGTH: 18
    56 <212> TYPE: RNA
    57 <213> ORGANISM: Nucleic Acid
    59 <400> SEQUENCE: ♠
                                                                           18
    60 auaaugaugu ccuugcuc
```

VERIFICATION SUMMARY

--

DATE: 03/04/2005

PATENT APPLICATION: US/10/018,716A

TIME: 15:21:52

Input Set : D:\LaBarbara 0476600.txt
Output Set: N:\CRF4\03042005\J018716A.raw

L:15 M:271 C: Current Filing Date differs, Replaced Current Filing Date